Mutations in the BCL2 gene, in particular the BCL-2-binding groove variants G101V or D103Y, were shown to confer resistance to chronic lymphocytic leukemia (CLL) patients treated with VEN [67]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.